Axitinib Approved for Patients with Advanced Renal Cell Carcinoma


axitinibAs of December 7, 2011 the Oncologic Drugs Advisory Committee voted to approve Axitinib CAS# 319460-85-0 (Inlyta) as a second-line treatment for patients with Advanced Renal Cell Carcinoma. This unanimous vote was based upon the findings of the phase 3 trial done in 2010, which compared Axitinib and Sorafenib. Axitinib, when compared to Sorafenib in clinical trials, was shown to significantly extend survival and disease progression.

Developed by Pfizer, Axitinib is a small molecule tyrosine kinase inhibitor. Phase 2 trials showed promise for patients with Breast Cancer, as Axitinib showed to inhibit tumor growth. Another trial, combining Axinitib with Gemcitabine initially showed improvement in patients with advanced pancreatic cancer. However, as of 2009 Pfizer announced that the results of this chemotherapy combination did not actually improve survival rates, when compared to the use of Gemcitabine alone. The trial was halted at that point.

Common side effects of Axitinib included diarrhea, hypertension, nausea and fatigue, of which all were considered manageable. Axitinib is an inhibitor for Vascular Endothelial Growth Factor receptors 1, 2 and 3, and hypertension is often considered to be a common side effect for these anti VEGF drugs. Reported dosage for trials of Axinitib were five milligrams, given twice daily.

LGM Pharma, an active pharmaceutical ingredient supplier, has built a reputation as being the “go to source” for hard to find API’s such as Axitinib, which is available on their website for R&D and drug development purposes.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share: